We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$120M
Cap. Flow %
-2.56%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Industrials 1.1%
3 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 7.22%
2,718,735
– –
BSX icon
2
Boston Scientific
BSX
$68.5B
$175M 3.71%
3,306,800
-73,100
-2% -$3.83M
HUM icon
3
Humana
HUM
$46.7B
$167M 3.54%
342,500
-6,200
-2% -$2.91M
ISRG icon
4
Intuitive Surgical
ISRG
$130B
$146M 3.1%
499,000
-121,500
-20% -$37.9M
BIIB icon
5
Biogen
BIIB
$30.4B
$143M 3.04%
556,800
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$143M 3.04%
1,615,210
– –
ELVN icon
7
Enliven Therapeutics
ELVN
$3.84B
$123M 2.61%
8,998,338
– –
MRK icon
8
Merck
MRK
$326B
$109M 2.31%
+1,055,000
New +$114M
IRON icon
9
Disc Medicine
IRON
$2.85B
$107M 2.27%
2,269,637
– –
LLY icon
10
Eli Lilly
LLY
$1.09T
$99.9M 2.12%
186,000
– –
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.14B
$98.4M 2.09%
2,169,500
– –
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$91.8M 1.95%
3,968,588
-210,000
-5% -$5.74M
UTHR icon
13
United Therapeutics
UTHR
$26.1B
$90.8M 1.93%
401,900
– –
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.88B
$86.1M 1.83%
2,896,074
-1,054,722
-27% -$21.7M
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$85.3M 1.81%
1,959,050
+1,045,400
+114% +$37.3M
BAX icon
16
Baxter International
BAX
$12.6B
$84.5M 1.8%
2,239,900
-1,135,100
-34% -$48.4M
EWTX icon
17
Edgewise Therapeutics
EWTX
$4.34B
$83.5M 1.77%
14,567,176
– –
THC icon
18
Tenet Healthcare
THC
$22.6B
$80.7M 1.71%
1,224,400
+263,900
+27% +$19.7M
XTNT icon
19
Xtant Medical Holdings
XTNT
$59.7M
$80.4M 1.71%
73,114,592
– –
EVH icon
20
Evolent Health
EVH
$421M
$78.8M 1.67%
2,895,632
– –
SYK icon
21
Stryker
SYK
$133B
$73.5M 1.56%
269,000
-2,400
-0.9% -$688K
TMO icon
22
Thermo Fisher Scientific
TMO
$214B
$72.8M 1.55%
143,800
-19,000
-12% -$10.1M
APLM icon
23
Apollomics
APLM
$40M
$67.4M 1.43%
179,936
+173,310
+2,616% +$84.7M
CI icon
24
Cigna
CI
$79.6B
$66.2M 1.41%
231,500
+70,500
+44% +$20.1M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.63B
$64.1M 1.36%
529,200
-124,800
-19% -$14.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.